Home Research-feed Channel Rankings GCT THU AI TR Open Data Must Reading

views: 33

Wilson H. Miller

Laboratory of Molecular Medicine, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY USA

Sign in to view more

Show Academic Trajectory

Ego Network

D-Core

Research Interests

Author Statistics

Experience

Education

Bio

None

Papers203 papers

Sort

By YearBy Citation

Moving towards personalized treatments of immune-related adverse events

Khashayar Esfahani, Arielle Elkrief, Cassandra Calabrese,Réjean Lapointe,Marie Hudson,Bertrand Routy,Wilson H. Miller,Leonard Calabrese

Nature Reviews Clinical Oncology, pp.1-12, (2020)

Bibtex

2011P The impact of pathological response (PR) on adjuvant chemotherapy (AC) decisions and patient outcomes in gastrointestinal cancers (GIC)

S. Bhalla,H. Zhu,J-Y. Lin,U. Özbek, E.J. Wilck,S. Chang,X. Chen, S. Ward,N. Harpaz, A. Polydorides,W. Miller, M.I. Fiel

Annals of Oncology, (2020)

Bibtex

Cost benefit analysis of robotic vs. Laparoscopic hepatectomy: A propensity matched retrospective cohort study of acs nsqip database

H. Miller, A.S. Kellish,A. Hakim, M. Wozniak,J. Gaughan, U. Atabek,F. Spitz,Y. Hong

Hpb, (2020)

Bibtex

Epigenetic Dysregulation Correlation with Oncotype Dx Scores: Novel Implication for Adjuvant Therapy in Breast Cancer

J. M. Badach,A. Lin,Y. Li, M. Wozniak, A. Melillo, N. De Leo,H. Miller,S. Li, J. Williamson,P. Zhang,F. R. Spitz, U. Atabek

ANNALS OF SURGICAL ONCOLOGY, no. SUPSUPPL 1 (2020): S12-S12

Bibtex

961P Genomic and transcriptomic profiling in head and neck tumours to identify treatment options: The WINTHER trial experience

I. Brana,Y. Loriot,R. Berger,E. Rubin,J. Rodon,W.H. Miller,A.M. Tsimberidou,P. Saintigny,R. Dienstmann,P. Nuciforo, C. Bescos,J. Lorente

Annals of Oncology, (2020)

Bibtex

The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma

Sathyen A. Prabhu, Omar Moussa,Wilson H. Miller,Sonia V. del Rincón

International Journal of Molecular Sciences, no. 11 (2020): 4055

Bibtex

FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC)

Toni K. Choueiri,Harriet M. Kluger,Saby George,Scott S. Tykodi,Timothy M. Kuzel, Ruth Perets,Suresh Nair,Giuseppe Procopio,Michael Anthony Carducci,Vincent Castonguay, Edmund Folefac,Chung-Han Lee

Journal of Clinical Oncology, (2020): 5007-5007

Bibtex

A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer

Wilson H. Miller,Quincy S. Chu,Nathaniel Bouganim,Derek J. Jonker,Gerald Batist, Najwa J Buhlaiga,Stephanie Lheureux,Jennifer L. Spratlin,Thierry Alcindor, Patricia S Smith, Joel Owen, Sara L. Zaknoen

Journal of Clinical Oncology, (2020): 3579-3579

Bibtex

A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2)

Reinhard Dummer,Shahneen Kaur Sandhu,Wilson H. Miller,Marcus O. Butler,Christian U. Blank, Eva Muñoz-Couselo,Howard A. Burris,Michael A. Postow,Bartosz Chmielowski,Mark R. Middleton,Carola Berking,Jessica Cecile Hassel

Journal of Clinical Oncology, (2020): 10022-10022

Bibtex

A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer

Quincy S. Chu,Derek J. Jonker,Diane M. Provencher,Wilson H. Miller,Nathaniel Bouganim,Anthony Frank Shields,Geoffrey Shapiro,Michael B. Sawyer,Stephanie Lheureux,Vanessa Samouelian,Walter H. Gotlieb, Khashayar Esfahani

Journal of Clinical Oncology, (2020): 3581-3581

Bibtex

P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma

Michele Maio,Matteo Carlino,Anthony Joshua,Elaine McWhirter,Antoni Ribas,Paolo Ascierto,Wilson Miller,Marcus Butler,Pier Ferrucci, Robert Zielinski,Michele Del Vecchio,Eduard Gasal

Journal for ImmunoTherapy of Cancer, (2020)

Bibtex

Reprogramming of nucleotide metabolism mediates synergy between epigenetic therapy and MAP Kinase inhibition

Tatiana Shorstova, Jie Su,Tiejun Zhao, Michael Dahabieh, Matthew Leibovitch, Mariana De Sa Tavares Russo,Daina Avizonis, Shivshankari Rajkumar,Ian R Watson,Sonia V Del Rincón,Wilson H Miller,William D Foulkes

Molecular cancer therapeutics, (2020)

WOSBibtex

MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression

William Yang, Elie Khoury, Qianyu Guo, Sathyen A Prabhu, Audrey Emond, Fan Huang, Christophe Gonçalves, Yao Zhan, Dany Plourde,Jessica N Nichol, Michael S Dahabieh,Wilson H Miller

Oncogene, pp.1-16, (2020)

WOSBibtex

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle,Marwan Fakih,Juanita Lopez,Manisha Shah,Ronnie Shapira-Frommer,Kazuhiko Nakagawa,Hyun Cheol Chung,Hedy L Kindler,Jose A Lopez-Martin,Wilson H Miller,Antoine Italiano, Steven Kao

The Lancet. Oncology, no. 10 (2020): 1353-1365

WOSBibtex

The MNK1/2 eIF4E Axis as a Potential Therapeutic Target in Melanoma

Sathyen A. Prabhu, Omar Moussa,Wilson H. Miller, Sonia V. del Rincón

International Journal of Molecular Sciences, (2020)

Bibtex

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Jordi Rodon,Jean-Charles Soria,Raanan Berger,Wilson H Miller,Eitan Rubin,Aleksandra Kugel,Apostolia Tsimberidou,Pierre Saintigny, Aliza Ackerstein,Irene Braña,Yohann Loriot, Mohammad Afshar

Nature medicine, pp.1, (2019)

Cited by86WOSBibtex

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

Arielle Elkrief, Layal El Raichani, Corentin Richard, Meriem Messaoudene, Wiam Belkaid, Julie Malo,Karl Belanger,Wilson Miller,Rahima Jamal,Nathalie Letarte,Philip Wong,Bertrand Routy

Oncoimmunology, no. 4 (2019)

WOSBibtex

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung,Sarina A Piha-Paul, Jose Lopez-Martin,Jan H M Schellens, Steven Kao,Wilson H Miller,Jean-Pierre Delord, Bo Gao,David Planchard,Maya Gottfried,Alona Zer,Shadia I Jalal

Journal of Thoracic Oncology, no. 4 (2019): 618-627

WOSBibtex

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

Khashayar Esfahani, Tho-Alfakar Al-Aubodah, Pamela Thebault,Réjean Lapointe,Marie Hudson,Nathalie A. Johnson, Dana Baran, Najwa Bhulaiga, Tomoko Takano,Jean-François Cailhier,Ciriaco A. Piccirillo,Wilson H. Miller

Nature Communications, no. 1 (2019): 1-9

Bibtex

1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

A Marabelle,M G Fakih,J Lopez,M Shah,R Shapira-Frommer,K Nakagawa,H C Chung,H L Kindler, J A Lopez-Martin,W Miller,A Italiano, S Kao

ANNALS OF ONCOLOGY, no. SUPnan (2019)

Bibtex

View All

Base Info Papers Patents Projects